What Does Fate Therapeutics, Inc. Do?

Total employees349
HeadquartersSan Diego
Founded2007

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company at the forefront of developing next-generation cellular immunotherapies for cancer and immune disorders. Utilizing its proprietary induced pluripotent stem cell (iPSC) product platform, the company engineers 'off-the-shelf' natural killer (NK) and T-cell product candidates. These therapies are designed to be universally available, overcoming limitations of patient-specific treatments. Fate Therapeutics aims to deliver transformative treatments by harnessing the power of the immune system through precisely engineered, renewable cell sources.

Where Is Fate Therapeutics, Inc.'s Headquarters?

Fate Therapeutics, Inc. officeFate Therapeutics, Inc. officeFate Therapeutics, Inc. officeFate Therapeutics, Inc. office
*Images sourced via web search. Rights belong to original owners

HQ Function

The San Diego headquarters serves as the central hub for Fate Therapeutics' research and development, clinical operations, cGMP manufacturing, and corporate administration.

Notable Features:

The facility includes state-of-the-art laboratories for iPSC research, cell engineering, cGMP manufacturing, and process development, alongside modern office spaces designed to foster collaboration.

Work Culture:

As a cutting-edge biotech firm, the work culture at Fate Therapeutics' HQ is characterized by innovation, scientific rigor, collaboration among multidisciplinary teams, and a strong sense of purpose driven by the potential to impact patient lives.

HQ Significance:

Located in a prominent San Diego biotech cluster, the headquarters benefits from proximity to leading research institutions, a rich talent pool, and a vibrant ecosystem of life science companies, fostering innovation and partnership opportunities.

Values Reflected in HQ: The headquarters' focus on advanced R&D and manufacturing facilities reflects the company's commitment to scientific excellence, innovation in cellular therapy, and the pursuit of groundbreaking treatments.

Location:

While Fate Therapeutics is headquartered in the United States, its impact and operations are global. The company conducts clinical trials for its iPSC-derived cell therapies in multiple countries, collaborating with international research institutions and clinical sites. The 'off-the-shelf' nature of its product candidates aims for worldwide accessibility, positioning Fate to address patient needs across diverse geographical regions. Their research and development efforts also contribute to the global scientific understanding of cellular immunotherapies.

Street Address:

12278 Scripps Summit Drive

City:

San Diego

State/Province:

CA

Country:

USA

Where Else Does Fate Therapeutics, Inc. Operate Around the World?

No additional office locations available.

Buying Intent Signals for Fate Therapeutics, Inc.

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Fate Therapeutics, Inc.? Meet the Executive Team

As of April 2025, Fate Therapeutics, Inc.' leadership includes:

J. Scott Wolchko - President and Chief Executive Officer
Wayne Chu, M.D. - Chief Medical Officer
Dulce Quintero, M.D. - Chief Scientific Officer
Edward J. Dulac III - Chief Financial Officer
Mark Plavsic, D.V.M., Ph.D. - Chief Technical Officer
Yu-Waye Chu - Chief Legal Officer and General Counsel

Who's Investing in Fate Therapeutics, Inc.?

Fate Therapeutics, Inc. has been backed by several prominent investors over the years, including:

BlackRock, Inc.
The Vanguard Group, Inc.
Redmile Group, LLC
State Street Corporation
FMR LLC (Fidelity Management & Research)
Perceptive Advisors LLC

What Leadership Changes Has Fate Therapeutics, Inc. Seen Recently?

Hire3
Exits1

Fate Therapeutics has made significant strategic appointments to its executive team over the past year (May 2023 - May 2024), notably strengthening its scientific, medical, and technical leadership with new C-suite executives. This includes new Chief Scientific, Chief Medical, and Chief Technical Officers, and a key transition for the former CSO to an advisory role.

Departures

Leonard S. W. Sender, M.D., Dr. Leonard S. W. Sender departed from his role as Chief Medical Officer.

New Appointments:

Mark Plavsic, D.V.M., Ph.D., Dr. Mark Plavsic appointed as new Chief Technical Officer.
Wayne Chu, M.D., Dr. Wayne Chu appointed as new Chief Medical Officer.
Dulce Quintero, M.D., Dr. Dulce Quintero appointed as new Chief Scientific Officer.
Daniel D. Shoemaker, Ph.D., Dr. Daniel D. Shoemaker transitioned from Chief Scientific Officer to Chief Scientific Advisor.

What Technology (Tech Stack) Is Used byFate Therapeutics, Inc.?

Discover the tools Fate Therapeutics, Inc. uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Fate Therapeutics, Inc. Email Formats and Examples

Fate Therapeutics, Inc. likely utilizes common corporate email formats. Based on standard practices, a common structure involves the first initial followed by the last name, or the first name separated from the last name by a dot, preceding the '@fatetherapeutics.com' domain.

[first_initial][last]@fatetherapeutics.com

Format

swolchko@fatetherapeutics.com

Example

75%

Success rate

What's the Latest News About Fate Therapeutics, Inc.?

Fate Therapeutics / Business WireMay 9, 2024

Fate Therapeutics, Inc. Reports First Quarter 2024 Financial Results and Business Updates

Fate Therapeutics announced its financial results for Q1 2024, highlighting progress in its iPSC-derived NK and T-cell therapy programs. Key updates included advancements in clinical trials for FT522 in B-cell lymphoma and FT819 in B-cell malignancies, along with a strong cash position to fund operations....more

Fate Therapeutics / Business WireApril 8, 2024

Fate Therapeutics, Inc. to Present Preclinical Data on IFN-alpha Armored CAR NK Cell Product Candidate FT522 and Multiplexed-Engineered CAR T-Cell Product Candidate FT825 (ONO-8250) at AACR 2024

Fate Therapeutics announced presentations at the American Association for Cancer Research (AACR) Annual Meeting 2024, showcasing preclinical data for FT522 (IFN-alpha armored CAR NK cell) and FT825/ONO-8250 (multiplexed-engineered CAR T-cell), highlighting their potential in cancer treatment....more

Fate Therapeutics / Business WireFebruary 27, 2024

Fate Therapeutics, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Fate Therapeutics reported its Q4 and full-year 2023 financial results, providing updates on its clinical programs, including the FT522 and FT819 studies, and its ongoing collaboration with ONO Pharmaceutical for FT825/ONO-8250. The company emphasized its focused strategy on advancing its core programs....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Fate Therapeutics, Inc., are just a search away.